Paloma Partners Management Co Takes $122,000 Position in Endo International plc – (ENDP)

Paloma Partners Management Co purchased a new position in Endo International plc – (NASDAQ:ENDP) (TSE:ENL) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,814 shares of the company’s stock, valued at approximately $122,000.

A number of other large investors have also modified their holdings of the stock. Quantitative Investment Management LLC acquired a new position in Endo International in the 4th quarter worth approximately $1,569,000. Amundi Pioneer Asset Management Inc. increased its holdings in Endo International by 235.6% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 96,033 shares of the company’s stock worth $745,000 after buying an additional 67,415 shares during the period. Hudson Bay Capital Management LP acquired a new position in Endo International in the 4th quarter worth approximately $388,000. Systematic Financial Management LP increased its holdings in Endo International by 22.5% in the 4th quarter. Systematic Financial Management LP now owns 190,550 shares of the company’s stock worth $1,477,000 after buying an additional 35,045 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in Endo International by 4.4% in the 4th quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock worth $1,720,000 after buying an additional 9,438 shares during the period. Institutional investors own 94.72% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities analysts recently weighed in on ENDP shares. Mizuho reiterated a “buy” rating and issued a $12.00 price target (down previously from $14.00) on shares of Endo International in a report on Wednesday, January 3rd. Leerink Swann started coverage on shares of Endo International in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Vetr upgraded shares of Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price target on the stock in a report on Tuesday, December 26th. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. Finally, BidaskClub lowered Endo International from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.68.

Shares of NASDAQ:ENDP opened at $5.94 on Friday. Endo International plc – has a 1 year low of $5.61 and a 1 year high of $14.15. The company has a market cap of $1,326.64, a PE ratio of 1.55 and a beta of 0.35. The company has a debt-to-equity ratio of 17.00, a quick ratio of 0.85 and a current ratio of 1.02.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.15. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The firm had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. During the same quarter last year, the firm posted $1.77 EPS. The business’s revenue was down 38.1% on a year-over-year basis. sell-side analysts expect that Endo International plc – will post 2.33 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/03/31/paloma-partners-management-co-takes-122000-position-in-endo-international-plc-endp.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply